NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) is the developer of a disruptive drug delivery platform, DehydraTECH™, that the company out-licenses to entities aiming to deliver healthier ingestion methods of cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. An article discussing the company’s technology reads: “Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) patented DehydraTECH™ drug delivery platform has already received some eight patents granted and nearly 50 pending worldwide, and the company has applied for one more to the USPTO. This is because, in lab studies, the proprietary technology has shown evidence of transporting active pharmaceutical ingredients (APIs) across the brain’s protective blood brain barrier, the company announced in an article published by the CFN Media Group (http://nnw.fm/oN1Xp).”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer